on DBV TECHNOLOGIES (EPA:DBV)
DBV Technologies adopts all resolutions at its General Meeting
On June 3, 2026, DBV Technologies, a biopharmaceutical company based in Châtillon, France, held its Combined General Meeting. Chaired by Michel de Rosen, the meeting saw the adoption of all resolutions proposed by the Board of Directors. Details of the resolutions are available on the company's website.
DBV Technologies, listed on Euronext and Nasdaq, specializes in developing treatments for food allergies and other immunological conditions. Its flagship technology, VIASKIN, uses epicutaneous immunotherapy to treat allergies, including peanut allergies in young children.
The company's headquarters are located in Châtillon, with North American operations based in New Jersey.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all DBV TECHNOLOGIES news